Gene targeting and influencing factors of therapeutic effect of Longchai Jiangxue Formula in the treatment of essential thrombocythemia

YU Xinyue; YANG Erpeng; LI Yumeng; SUN Yan; NIU Jicong; CHEN Ke; ZOU Jixuan; WANG Mingjing; LIU Weiyi; LYU Yan; CHEN Zhuo; HU Xiaomei

doi:10.16025/j.1674-1307.2024.12.006

您当前的位置：

首页 >

文章列表页 >

Gene targeting and influencing factors of therapeutic effect of Longchai Jiangxue Formula in the treatment of essential thrombocythemia

更新时间：2025-01-08

- Gene targeting and influencing factors of therapeutic effect of Longchai Jiangxue Formula in the treatment of essential thrombocythemia
- Beijing Journal of Traditional Chinese Medicine Vol. 43, Issue 12, Pages: 1352-1358(2024)
- 作者机构：
  
  1.中国中医科学院研究生院，北京 100700
  2.中国中医科学院西苑医院血液科，北京 100091
- 作者简介：
- 基金信息：
- DOI：10.16025/j.1674-1307.2024.12.006
  CLC：
- Published：25 December 2024，
  
  Received：07 July 2023，
- 稿件说明：
移动端阅览
余心悦，杨二鹏，李雨蒙，等.龙柴降血方治疗原发性血小板增多症的基因靶向性及疗效影响因素［J］.北京中医药，2024，43（12）：1352-1358.

YU Xinyue,YANG Erpeng,LI Yumeng,et al.Gene targeting and influencing factors of therapeutic effect of Longchai Jiangxue Formula in the treatment of essential thrombocythemia[J]. Beijing Journal of Traditional Chinese Medicine,2024,43(12):1352-1358.
余心悦，杨二鹏，李雨蒙，等.龙柴降血方治疗原发性血小板增多症的基因靶向性及疗效影响因素［J］.北京中医药，2024，43（12）：1352-1358. DOI： 10.16025/j.1674-1307.2024.12.006.

YU Xinyue,YANG Erpeng,LI Yumeng,et al.Gene targeting and influencing factors of therapeutic effect of Longchai Jiangxue Formula in the treatment of essential thrombocythemia[J]. Beijing Journal of Traditional Chinese Medicine,2024,43(12):1352-1358. DOI： 10.16025/j.1674-1307.2024.12.006.

摘要

目的

探讨龙柴降血方治疗原发性血小板增多症（ET）的基因靶向性及疗效优势。

方法

基于二代基因测序结果，结合血液学疗效和抗凝疗效，分析龙柴降血方治疗ET的基因靶向性。通过二元

Logistic

回归方法，分析观察组和对照组的血液学疗效差异，得到龙柴降血方的疗效优势。

结果

在血液学疗效方面，观察组驱动基因CALR+患者血液学缓解率、无非驱动基因突变患者的血液学缓解率及单基因突变患者的血液学缓解率均较对照组升高（

0.05）。在抗凝疗效方面，观察组驱动基因JAK2+患者高凝状态发生率及双基因突变患者高凝状态发生率均较对照组降低（

0.05）。单因素和多因素

Logistic

回归分析结果显示，高血压、CALR+以及PLT计数≥600×10

/L是龙柴降血方疗效的影响因素。

结论

有驱动基因CALR+、单基因突变以及无非驱动基因突变的ET患者，在常规治疗基础上联合龙柴降血方可以获得更高的血液学缓解率；有驱动基因JAK2+

、

单基因突变以及双基因突变的ET患者，在常规治疗上联合龙柴降血方可以获得更好的抗凝效果；ET患者伴有高血压、CALR+或PLT计数≥600×10

/L时，在基础治疗方案上联合龙柴降血方可以提高血液学疗效。

Abstract

关键词

龙柴降血方原发性血小板增多症基因突变

Keywords

references

BARBUI T,THIELE J,GISSLINGER H,et al.The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms:document summary and in-depth discussion[J].Blood Cancer J,2018,8(2):15.

TEFFERI A,LASHO TL,GUGLIELMELLI P,et al.Targeted deep sequencing in polycythemia vera and essential thrombocythemia[J].Blood Adv,2016,1(1):21-30.

KNUDSEN TA,SKOV V,STEVENSON K,et al.Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses[J].Blood Adv, 2022,6(7):2107-2119.

MAIFREDE S,LE BV,NIEBOROWSKA-SKORSKA M,et al.TET2 and DNMT3A mutations exert divergent effects on DNA repair and sensitivity of leukemia cells to PARP inhibitors[J].Cancer Res,2021,81(19):5089-5101.

WESTERMANN J,BULLINGER L.Precision medicine in myeloid malignancies[J].Semin Cancer Biol,2022,84:153-169.

ARBER DA,ORAZI A,HASSERJIAN R,et al.The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J].Blood,2016,127(20):2391-2405.

陈信义,杨文华.中医血液病学[M].北京：中国中医药出版社,2019：170.

PUGLIANINI OC,PEKER D,ZHANG L,et al.Essential thrombocythemia and post-essential thrombocythemia myelofibrosis:updates on diagnosis,clinical aspects,and management[J].Lab Med,2023,54(1):13-22.

TEFFERI A,BARBUI T.Polycythemia vera and essential thrombocythemia:2021 update on diagnosis,risk-stratification and management[J].Am J Hematol,2020,95(12):1599-1613.

沈悌,赵永强.血液病诊断及疗效标准[M].4版.北京：科学出版社,2018:201-203.

王静,张侠.恶性肿瘤患者高凝状态的危险因素、发生机制及实验室检测[J].检验医学与临床,2015,（15）：2284-2287.

刘俊青,刘春香,韩金凤.中医药治疗恶性肿瘤患者血液高凝状态的研究进展[J].广西医学,2021,（3）：363-366.

董林剑,李元海.血栓弹力图的临床应用及发展[J].安徽医药,2015,（5）：817-820.

肖志坚.原发性血小板增多症诊断与治疗中国专家共识(2016年版)[J].中华血液学杂志,2016,(10):833-836.

MAZZA GL,MEAD-HARVEY C,MASCARENHAS J,et al.Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a:a post-hoc analysis of the MPN-RC 111 and 112 trials[J].Lancet Haematol,2022,9(1):38-48.

BARBUI T,GHIRARDI A,MASCIULLI A,et al.Second cancer in philadelphia negative myeloproliferative neoplasms(MPN-K).A nested case-control study[J].Leukemia,2019,33(8):1996-2005.

LIU D,XU Z,ZHANG P,et al.Conventional interferon-α 2b versus hydroxyurea for newly-diagnosed patients with polycythemia vera in a real world setting:a retrospective study based on 286 patients from a single center[J].Haematologica,2022,107(4):991-995.

MCLORNAN DP,POPE JE,GOTLIB J,et al.Current and future status of JAK inhibitors[J].Lancet,2021,398(10302):803-816.

田芮萍,秦兰.中西医治疗原发性血小板增多症现况[J]. 医学理论与实践,2022,35(23):3985-3987,3990.

王雪梅,刘松山,王译.原发性血小板增多症中西医治疗进展[J].世界最新医学信息文摘（连续型电子期刊）,2019,19(20):138-140.

ARBER DA,ORAZI A,HASSERJIAN R,et al.The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J].Blood,2016,127(20):2391-2405.

朱世荣.龙柴降血方治疗BCR-ABL阴性骨髓增殖性肿瘤的靶向性及对凝血功能影响[D].北京：北京中医药大学,2020:30-31.

李芋锦.基于蛋白组学的龙柴降血方治疗原发性血小板增多症临床及机制研究[D].北京：中国中医科学院,2022:43-44.

YANG E,LYU Y,WANG Z,et al.Coagulation status and determinants of possible aspirin resistance in patients with essential thrombocythemia[J].Front Med (Lausanne),2022,9:1092281.

BABAKHANLOU R,MASAROVA L,VERSTOVSEK S.A review of essential thrombocythemia and its complications[J].Clin Adv Hematol Oncol,2023,21(2):76-84.

TEFFERI A,GUGLIELMELLI P,LASHO TL,et al.Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera[J].Br J Haematol,2020,189(2):291-302.

LI J,PEI L,LIANG S,et al.Gene mutation analysis using next-generation sequencing and its clinical significance in patients with myeloid neoplasm:a multi-center study from China[J].Cancer Med,2023,12(8):9332-9350.

ZHANG L,YE X,LUO S,et al.Clinical features and next-generation sequencing landscape of essential thrombocythemia,prefibrotic primary myelofibrosis,and overt fibrotic primary myelofibrosis:a Chinese monocentric retrospective study[J].J Cancer Res Clin Oncol,2023,149(6):2383-2392.

ROGER I,MILARA J,MONTERO P,et al.The role of JAK/STAT molecular pathway in vascular remodeling associated with pulmonary hypertension[J].Int J Mol Sci,2021,22(9):4980.

DUAN B,LI Y,GENG H,et al.Naringenin prevents pregnancy-induced hypertension via suppression of JAK/STAT3 signalling pathway in mice[J].Int J Clin Pract, 2021,75(10):14509.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

No data

Related Author

No data

Related Institution

No data

⁰